HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Kehong Zhang Selected Research

Hyperkinesis

9/2005Atomoxetine blocks motor hyperactivity in neonatal 6-hydroxydopamine-lesioned rats: implications for treatment of attention-deficit hyperactivity disorder.
8/2002Serotonin transporter binding increases in caudate-putamen and nucleus accumbens after neonatal 6-hydroxydopamine lesions in rats: implications for motor hyperactivity.
6/2002Effects of norepinephrine and serotonin transporter inhibitors on hyperactivity induced by neonatal 6-hydroxydopamine lesioning in rats.
5/2002Plasticity of dopamine D4 receptors in rat forebrain: temporal association with motor hyperactivity following neonatal 6-hydroxydopamine lesioning.
4/2002Effects of dopamine D4 receptor-selective antagonists on motor hyperactivity in rats with neonatal 6-hydroxydopamine lesions.
2/2002Stereoselective effects of methylphenidate on motor hyperactivity in juvenile rats induced by neonatal 6-hydroxydopamine lesioning.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Kehong Zhang Research Topics

Disease

6Hyperkinesis
09/2005 - 02/2002
5Attention Deficit Disorder with Hyperactivity (Attention Deficit Hyperactivity Disorder)
09/2005 - 02/2002
4Inflammation (Inflammations)
01/2022 - 01/2021
2Infections
01/2022 - 01/2022
2Schizophrenia (Dementia Praecox)
08/2004 - 12/2002
1Autoimmune Diseases (Autoimmune Disease)
01/2022
1Rheumatoid Arthritis
01/2021
1Multidrug-Resistant Tuberculosis (Drug-Resistant Tuberculosis)
01/2020
1Extensively Drug-Resistant Tuberculosis
01/2020
1Mental Disorders (Mental Disorder)
09/2007
1Coloboma (Colobomas)
04/2003
1Bipolar Disorder (Manic Depressive Psychosis)
05/2002

Drug/Important Bio-Agent (IBA)

6Oxidopamine (6 Hydroxydopamine)IBA
04/2003 - 02/2002
4Serotonin (5 Hydroxytryptamine)IBA
08/2002 - 04/2002
4Dopamine (Intropin)FDA LinkGeneric
06/2002 - 02/2002
3salicylhydroxamic acid (SHAM)IBA
09/2005 - 04/2002
3Dopamine D4 Receptors (Dopamine D4 Receptor)IBA
08/2004 - 04/2002
2LipoxygenasesIBA
01/2022 - 01/2021
2LipidsIBA
01/2022 - 01/2021
2Norepinephrine (Noradrenaline)FDA LinkGeneric
09/2005 - 06/2002
2Methylphenidate (Ritalin)FDA LinkGeneric
06/2002 - 02/2002
1Sulfasalazine (Azulfidine)FDA LinkGeneric
01/2022
1Pharmaceutical PreparationsIBA
01/2022
1EnzymesIBA
01/2022
1celastrolIBA
01/2022
1Dinoprostone (PGE2)FDA Link
01/2022
1GlycosidesIBA
01/2021
1Prostaglandin-Endoperoxide Synthases (Cyclooxygenase)IBA
01/2021
1Unsaturated Fatty Acids (Polyunsaturated Fatty Acids)IBA
01/2021
1Selective Estrogen Receptor Modulators (SERM)IBA
01/2020
1Biological ProductsIBA
09/2007
1Desipramine (Pertofrane)FDA LinkGeneric
09/2005
1Hypnotics and Sedatives (Sedatives)IBA
09/2005
1Atomoxetine Hydrochloride (Strattera)FDA LinkGeneric
09/2005
1nisoxetineIBA
09/2005
1Dopamine Plasma Membrane Transport Proteins (Dopamine Transporter)IBA
04/2003
1NeurotoxinsIBA
04/2003
1Nitric Oxide (Nitrogen Monoxide)FDA Link
12/2002
1Antipsychotic Agents (Antipsychotics)IBA
12/2002
1Serotonin Plasma Membrane Transport Proteins (Serotonin Transporter)IBA
08/2002
1Amphetamine (Amfetamine)FDA LinkGeneric
06/2002
12- (2- hydroxyethylsulfanyl)- 3- methyl- 5- nitro- 1,4- naphthoquinoneIBA
05/2002
1S 18126IBA
04/2002
13- ((4- (4- chlorophenyl)piperazin- 1- yl)methyl)- 1H- pyrrolo(2,3- b)pyridineIBA
04/2002
1KetanserinIBA
04/2002

Therapy/Procedure

3Therapeutics
01/2022 - 01/2020
1Chinese Traditional Medicine (Traditional Chinese Medicine)
01/2021